STOCK TITAN

[SCHEDULE 13G/A] Intensity Therapeutics, Inc. Common stock SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Schedule 13G/A filed for Intensity Therapeutics, Inc. (INTS) reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 1,237,113 shares of the issuer's common stock, representing 2.56% of the class. The filing states Armistice Capital is the investment manager of the Master Fund, the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over the reported shares. Mr. Boyd, as managing member, is likewise reported with shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to its Investment Management Agreement.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Armistice and its managing member report a modest 2.56% shared stake, a routine disclosure with limited market impact.

This Schedule 13G/A confirms a passive ownership disclosure rather than an activist or control-seeking filing: the stake is below 5% and is reported as shared voting/dispositive power through an investment manager arrangement. For investors, this is transparency about an institutional exposure but not a material ownership shift likely to change control or strategy.

TL;DR: The filing documents appropriate joint reporting and allocation of voting/dispositive authority under an investment management agreement.

The filing clarifies roles: Armistice Capital as investment manager and Steven Boyd as managing member disclose shared authority over the Master Fund's holdings and include the Master Fund's disclaimer of direct beneficial ownership due to the management agreement. This aligns with standard governance disclosures and joint-filing practices, reducing ambiguity about who exercises voting rights.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

INTENSITY THERAPEUTICS INC

NASDAQ:INTS

INTS Rankings

INTS Latest News

INTS Latest SEC Filings

INTS Stock Data

22.53M
54.78M
13.25%
6.87%
1.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SHELTON